These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 8833398)
1. High-dose cytarabine and recombinant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia. Schiller G; Emmanoulides C; Iastrebner MC; Lee M; Naeim F Leuk Lymphoma; 1996 Feb; 20(5-6):427-34. PubMed ID: 8833398 [TBL] [Abstract][Full Text] [Related]
2. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Giralt S; Estey E; Albitar M; van Besien K; Rondón G; Anderlini P; O'Brien S; Khouri I; Gajewski J; Mehra R; Claxton D; Andersson B; Beran M; Przepiorka D; Koller C; Kornblau S; Kørbling M; Keating M; Kantarjian H; Champlin R Blood; 1997 Jun; 89(12):4531-6. PubMed ID: 9192777 [TBL] [Abstract][Full Text] [Related]
3. Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups. Bassan R; Chiodini B; Lerede T; Giussani U; Oldani E; Buelli M; Rossi A; Viero P; Rambaldi A; Barbui T Hematol J; 2002; 3(4):193-200. PubMed ID: 12189565 [TBL] [Abstract][Full Text] [Related]
4. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. Harousseau JL; Witz B; Lioure B; Hunault-Berger M; Desablens B; Delain M; Guilhot F; Le Prise PY; Abgrall JF; Deconinck E; Guyotat D; Vilque JP; Casassus P; Tournilhac O; Audhuy B; Solary E J Clin Oncol; 2000 Feb; 18(4):780-7. PubMed ID: 10673519 [TBL] [Abstract][Full Text] [Related]
5. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group. Alonzo TA; Kobrinsky NL; Aledo A; Lange BJ; Buxton AB; Woods WG J Pediatr Hematol Oncol; 2002 Nov; 24(8):627-35. PubMed ID: 12439034 [TBL] [Abstract][Full Text] [Related]
6. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia. Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264 [TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [TBL] [Abstract][Full Text] [Related]
8. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia. Demirer T; Buckner CD; Appelbaum FR; Petersen FB; Rowley S; Weaver CH; Lilleby K; Sanders J; Chauncey T; Storb R Bone Marrow Transplant; 1995 Jun; 15(6):915-22. PubMed ID: 7581091 [TBL] [Abstract][Full Text] [Related]
9. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387 [TBL] [Abstract][Full Text] [Related]
10. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia. He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371 [TBL] [Abstract][Full Text] [Related]
11. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study. Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091 [TBL] [Abstract][Full Text] [Related]
12. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same? Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584 [TBL] [Abstract][Full Text] [Related]
13. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Rowe JM; Andersen JW; Mazza JJ; Bennett JM; Paietta E; Hayes FA; Oette D; Cassileth PA; Stadtmauer EA; Wiernik PH Blood; 1995 Jul; 86(2):457-62. PubMed ID: 7605984 [TBL] [Abstract][Full Text] [Related]
14. Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial. He XY; Elson P; Pohlman B; Lichtin A; Hussein M; Andresen S; Kalaycio M BMC Cancer; 2002 May; 2():12. PubMed ID: 12019034 [TBL] [Abstract][Full Text] [Related]
15. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia. Demirer T; Petersen FB; Bensinger WI; Appelbaum FR; Fefer A; Rowley S; Sanders J; Chauncey T; Storb R; Lilleby K; Buckner CD Bone Marrow Transplant; 1996 Jul; 18(1):29-34. PubMed ID: 8831992 [TBL] [Abstract][Full Text] [Related]
16. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Robak T; Wrzesień-Kuś A; Lech-Marańda E; Kowal M; Dmoszyńska A Leuk Lymphoma; 2000 Sep; 39(1-2):121-9. PubMed ID: 10975390 [TBL] [Abstract][Full Text] [Related]
17. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763 [TBL] [Abstract][Full Text] [Related]
18. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Rossi HA; O'Donnell J; Sarcinelli F; Stewart FM; Quesenberry PJ; Becker PS Leukemia; 2002 Mar; 16(3):310-5. PubMed ID: 11896533 [TBL] [Abstract][Full Text] [Related]
19. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group. Kern W; Aul C; Maschmeyer G; Kuse R; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W Ann Hematol; 1998 Sep; 77(3):115-22. PubMed ID: 9797080 [TBL] [Abstract][Full Text] [Related]
20. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]